Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial

BACKGROUND: Erlotinib combined with whole-brain radiotherapy (WBRT) demonstrated a favorable objective response rate in a phase II single-arm trial of non–small cell lung cancer (NSCLC) patients with brain metastases. We assessed whether concurrent erlotinib with WBRT is safe and benefits patients i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Yang, Zhenzhou, Zhang, Yan, Li, Rongqing, Yisikandaer, Abulimiti, Ren, Biyong, Sun, Jianguo, Li, Jianjun, Chen, Long, Zhao, Ren, Zhang, Juying, Xia, Xuefeng, Liao, Zhongxing, Carbone, David P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168818/
https://ncbi.nlm.nih.gov/pubmed/33331923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa281
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak